RA Capital Management 13F holdings, Q2 2012
Holdings as of June 30, 2012 · filings on SEC EDGAR · latest filing →
RA Capital Management disclosed 26 US equity positions worth $222.7m in its Q2 2012 13F filing. The largest position was NVAX at 9.2% of the reported book, followed by POZEN INC and DYAX CORP. Against the Q1 2012 filing, it opened 8 new positions, added to 9 and reduced 8 among the top 26 holdings.
What did RA Capital Management own in Q2 2012? Top 26 positions
| # | Stock | Sector | Weight | Value | Shares | Δ shares | vs Q1 2012 |
|---|---|---|---|---|---|---|---|
| 1 | NVAX NOVAVAX INC | Healthcare | 9.2% | $20.6m | 13,200,000 | 4300% | added |
| 2 | POZEN INC | 8.2% | $18.2m | 2,919,071 | -1% | reduced | |
| 3 | DYAX CORP | 8.2% | $18.2m | 8,528,940 | 10% | added | |
| 4 | ARTHROCARE CORP | 7.4% | $16.5m | 562,412 | -18% | reduced | |
| 5 | ANACOR PHARMACEUTICALS INC | 7.0% | $15.6m | 2,405,177 | 200% | added | |
| 6 | SGMOQ SANGAMO BIOSCIENCES INC | Healthcare | 5.4% | $12.0m | 2,165,888 | 207% | added |
| 7 | DERMA SCIENCES INC | 5.4% | $11.9m | 1,253,419 | 20% | added | |
| 8 | VNDA VANDA PHARMACEUTICALS INC | Healthcare | 5.1% | $11.4m | 2,599,844 | 1% | added |
| 9 | IDENIX PHARMACEUTICALS INC | 4.4% | $9.8m | 948,824 | – | new | |
| 10 | SYNERGY PHARMACEUTICALS DEL | 4.2% | $9.4m | 1,975,544 | – | new | |
| 11 | XOMA CORP DEL | 4.1% | $9.1m | 3,061,415 | -44% | reduced | |
| 12 | CORONADO BIOSCIENCES INC | 4.0% | $9.0m | 1,775,154 | 4157% | added | |
| 13 | ACAD ACADIA PHARMACEUTICALS INC | Healthcare | 4.0% | $8.9m | 5,083,833 | -4% | reduced |
| 14 | NBIX NEUROCRINE BIOSCIENCES INC | Healthcare | 2.9% | $6.5m | 823,142 | -3% | reduced |
| 15 | YM BIOSCIENCES INC | 2.8% | $6.3m | 3,163,974 | 38% | added | |
| 16 | SEQUENOM INC | 2.8% | $6.1m | 1,510,000 | -73% | reduced | |
| 17 | BCRX BIOCRYST PHARMACEUTICALS | Healthcare | 2.7% | $6.0m | 1,504,031 | -51% | reduced |
| 18 | VSTM VERASTEM INC | Healthcare | 2.6% | $5.9m | 605,600 | 0% | held |
| 19 | ENDOCYTE INC | 2.4% | $5.4m | 654,704 | – | new | |
| 20 | VENTRUS BIOSCIENCES INC | 2.4% | $5.3m | 1,245,000 | 133% | added | |
| 21 | SENOMYX INC | 2.0% | $4.6m | 1,939,508 | – | new | |
| 22 | SPECTRUM PHARMACEUTICALS INC | 1.5% | $3.3m | 210,597 | – | new | |
| 23 | MELA SCIENCES INC | 0.7% | $1.6m | 500,000 | – | new | |
| 24 | REPROS THERAPEUTICS INC | 0.3% | $705.0k | 77,600 | -88% | reduced | |
| 25 | DYNAVAX TECHNOLOGIES CORP | 0.1% | $324.0k | 75,000 | – | new | |
| 26 | SAVIENT PHARMACEUTICALS INC | 0.1% | $268.0k | 1,000,000 | – | new |
Weights are shares of the reported long US equity book (options excluded). Values are as filed, normalised to whole dollars. Share changes compare against the immediately preceding filing only.